Comparative Pharmacology
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LEGEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRI LO SPRINTEC versus TRI LEGEST FE.
TRI LO SPRINTEC vs TRI-LEGEST FE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Tri-Legest FE is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It prevents ovulation by inhibiting gonadotropin release (FSH and LH) and alters cervical mucus and endometrial lining to impede sperm penetration and implantation.
Prevention of pregnancy
Prevention of pregnancy
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet orally once daily for 28-day cycle: 21 days active tablets (norethindrone/ethinyl estradiol) followed by 7 days placebo. For contraception only.
None Documented
None Documented
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Norethindrone: 7-8 hours; Ethinyl estradiol: 18 hours (terminal). Steady-state reached after 7 days; clinical contraceptive efficacy requires consistent dosing.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Ethinyl estradiol is metabolized primarily by CYP3A4; norethindrone acetate is hydrolyzed to norethindrone, which is metabolized by reduction and conjugation (glucuronidation and sulfation).
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: ~60% (metabolites), Fecal: ~30% (metabolites), Biliary: minor (~5% as conjugates)
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: >95% bound to albumin.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Norethindrone: 3-4 L/kg; Ethinyl estradiol: 2-3 L/kg. Indicates extensive tissue distribution.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: Norethindrone ~60% (first-pass metabolism); Ethinyl estradiol ~45-55% (first-pass and gut wall metabolism).
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No specific guidelines exist; use with caution in renal impairment due to potential for fluid retention and hyperkalemia.
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in severe hepatic disease or active liver disease (Child-Pugh Class C). Use with caution in mild to moderate impairment (Child-Pugh A/B) without specific dose adjustment.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Not indicated in premenarchal females; after menarche, same dosing as adults but only for contraception after assessment of skeletal maturity.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for use in postmenopausal women; no specific dose adjustments in elderly females of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with number of cigarettes smoked. Women over 35 who smoke should not use combination oral contraceptives.
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Cigarette smoking increases risk of serious cardiovascular events","Increased risk of hepatic neoplasia (benign and malignant)","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid metabolic effects"]
["Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction)","Hepatic disease (jaundice, liver tumors)","Hypertension","Gallbladder disease","Carbohydrate and lipid metabolism effects","Headache/migraine","Bleeding irregularities","Depression","Cervical cancer risk"]
["Known or suspected pregnancy","Current or history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal uterine bleeding","Benign or malignant liver tumor or active liver disease","Hypersensitivity to any component","Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir"]
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer","Liver tumors (benign or malignant) or active liver disease","Hypersensitivity to any component","Women over 35 who smoke"]
Data Pending Review
Data Pending Review
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically meaningful. Avoid excessive alcohol intake as it may impair liver metabolism and increase risk of breakthrough bleeding.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
Pregnancy category X. Combination hormonal contraceptives (CHCs) are contraindicated in pregnancy. First trimester use may cause small increased risk of limb reduction defects and cardiovascular anomalies; second and third trimester exposure is associated with masculinization of female fetuses due to progestin component. Discontinue immediately if pregnancy occurs.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Small amounts of steroids pass into breast milk (M/P ratio unknown, estimated <1%). CHCs may reduce milk production and composition, especially with early postpartum use. Avoid use during lactation; progestin-only methods preferred. Use only if benefits outweigh risks.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
Not applicable; combination hormonal contraceptives are contraindicated in pregnancy. No dose adjustments are recommended or studied. Discontinue immediately upon pregnancy diagnosis. Alternative contraception should be used if needed.
Category C
Category C
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Tri-Legest Fe is a combination oral contraceptive containing estradiol and norethindrone. Its 91-day extended-cycle regimen (84 active pills followed by 7 low-dose estrogen pills) reduces menstruation frequency to once every 3 months. Use caution in patients with migraine with aura, hypertension, or smoking over age 35 due to increased thromboembolic risk. The low-dose estrogen pills (10 mcg ethinyl estradiol) during week 13 help maintain hormone levels and reduce breakthrough bleeding. Advise patients to take at the same time daily; missed pills increase pregnancy risk.
Take one tablet daily at the same time; missed doses increase pregnancy risk.Use backup contraception for 7 days after missing 2 or more pills.Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.Avoid smoking while on this medication, especially if over 35.May cause irregular bleeding initially; contact provider if persistent.
Take one pill daily at the same time; missing pills increases pregnancy risk.You will have a period only once every 3 months (during the last week of each cycle).Use backup contraception if you miss 2 or more active pills in a row.Common side effects include spotting, nausea, breast tenderness, and mood changes.Do not smoke while taking this medication, especially if over 35.This does not protect against STIs; use condoms for prevention.Inform your doctor if you have migraines, high blood pressure, or a history of blood clots.